<DOC>
	<DOCNO>NCT01566201</DOCNO>
	<brief_summary>Inhibition interleukin-1 ( IL-1 ) activity patient RA without CAD ameliorate vascular LV function . Moreover , data specie show beneficial effect treatment LV function experimental myocardial infarction . The purpose study investigate whether anakinra , IL-1 receptor antagonist , improve vascular leave ventricular ( LV ) function patient coronary artery disease ( CAD ) coexistent rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>Effects Interleukin-1 Inhibition Vascular Left Ventricular Function Rheumatoid Arthritis Patients With Coronary Artery Disease</brief_title>
	<detailed_description>The inflammatory process observed patient rheumatoid arthritis ( RA ) strongly link enhance interleukin-1 ( IL-1 ) activity . Increased IL-1 activity cause myocardial cell damage endothelial dysfunction . The adverse effect IL-1 myocardial endothelial cell mediate enhanced nitrooxidative stress promotion apoptotic cardiomyocyte death increase nitrooxidative stress inflammation . Anakinra , recombinant form human IL-1 receptor antagonist , commonly use treatment RA . Experimental data indicate administration anakinra acute myocardial infarction ameliorate cardiac remodel reduce cardiomyocyte apoptosis . Moreover , previous study show treatment anakinra reduce IL-1-mediated nitrooxidative stress apoptotic marker lead improvement Tissue Doppler speckle tracking-derived parameter leave ventricular ( LV ) function RA patient . However define whether inhibition IL-1 activity anakinra show beneficial effect endothelial , coronary , arterial LV systolic diastolic function patient coronary artery disease ( CAD ) . For purpose , study 60 patient CAD coexistent RA ( American Rheumatism Association criterion ) well 20 patient RA without CAD . All subject inadequate response disease modify antirheumatic drug ( DMARDs ) corticosteroids go initiate treatment IL-1 activity inhibitor ( anakinra ) . All patient treatment statin cardioactive medication respectively , last 6 month . In 20 patient RA , presence CAD exclude non-invasive test and/or negative recent coronary arteriogram . In double-blind , placebo-controlled fashion , patient randomize receive single injection anakinra ( 100 mg s.c. ) placebo . After 48-hours patient crossed alternate treatment ( placebo anakinra ) measurement examine marker repeat . The 48h interval 2 consecutive study decide secure sufficient wash-out period anakinra accordance drug 's half-life time . Twenty asymptomatic subject match age sex RA patient normal ECG , echocardiogram , treadmill test select healthy control subject among subject attend cardiology outpatient ' clinic . At baseline RA subject control well 3-hours single injection anakinra RA subject , assess mean echocardiography follow parameter ) LV dimension , fractional shorten wall motion score index ( WMSI ) b ) systolic ( Sm ) , early diastolic ( Em ) late diastolic ( Am ) myocardial velocity mitral annulus use tissue Doppler ( TDI ) well ratio E wave mitral inflow measure pulsed wave Doppler mean Em index LV diastolic filling pressure c ) LV longitudinal , circumferential radial strain strain rate , well Global Longitudinal strain Torsion use speckle track echocardiography ) coronary flow reserve ( CFR ) adenosine infusion ass coronary vasomotor function e ) flow-mediated endothelial-dependent dilation brachial artery ( FMD ) assess peripheral endothelial function f ) diameter aorta systole diastole calculate aortic strain index local aortic property . At time period , measure blood sample ) nitrotyrosine ( NT ) , protein carbonyl ( PC ) malondialdehyde ( MDA ) ass nitrooxidative stress b ) soluble Fas Fas-ligand ) ass apoptosis c ) interleukin-1b tumor necrosis factor-a ass inflammation</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Patients rheumatoid arthritis coexistent coronary artery disease without CAD inadequate response disease modify antirheumatic drug ( DMARDs ) corticosteroids go initiate treatment interleukin1 inhibitor . Familiar hyperlipidemia Diabetes mellitus Chronic obstructive pulmonary disease asthma , moderate severe valvular heart disease , primary cardiomyopathy , malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Arterial stiffness</keyword>
	<keyword>Endothelial function</keyword>
	<keyword>Left ventricular function</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Nitrooxidative stress</keyword>
</DOC>